Currently Viewing:
Newsroom
Currently Reading
Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population
August 28, 2018 – Laura Joszt
This Week in Managed Care: August 24, 2018
August 24, 2018
Dose-Confirmation Study for Hemophilia B Gene Therapy Underway
August 24, 2018 – Laura Joszt
NCCN Releases New Guidelines for Rare Cancers During Pregnancy
August 23, 2018 – Samantha DiGrande
Tracking ctDNA Levels Can Quickly Predict Response to Lymphoma Therapy
August 22, 2018 – Laura Joszt
CAR T Signaling Differences Could Point the Way to More Targeted Treatments, Study Says
August 21, 2018 – Allison Inserro
Payment Reform in Cancer Needs to Engage and Reward Patients, Experts Assert
August 21, 2018 – Laura Joszt
PARP Inhibitor Increases PFS Over Chemotherapy in Advanced Breast Cancers, Study Finds
August 16, 2018 – Samantha DiGrande
AI Platform Can Identify Personalized Drug Combinations to Treat Multiple Myeloma
August 16, 2018 – Laura Joszt

Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population

Laura Joszt
As cure rates for young patients with Hodgkin lymphoma (HL) improve, the historically negative impact of treatments has to be considered. However, a new study has found that over time, childbearing rates for female survivors of HL have improved to the point of approaching the rates of the general population.
As cure rates for young patients with Hodgkin lymphoma (HL) improve, the historically negative impact of treatments has to be considered. A new study in Journal of Clinical Oncology analyzed childbearing and time to first childbirth after HL diagnosis in patients who only received first-line treatment.

The researchers used Swedish registers to study 449 women between the ages of 18 and 40 years who were diagnosed with HL between 1992 and 2009. The patients in the study were in remission 9 months after their diagnosis and they were age- and calendar-year–matched to 2210 comparators.

“Trends in childbearing over calendar time and treatments can provide caregivers with insight in how to counsel patients about their future fertility and family planning,” the authors wrote.

Among the patients with HL, 22.5% (101) had a childbirth during the follow-up period. Among the comparators, the childbirth rate was 28.9%. While the childbirth rate among patients with HL increased over time, as treatment according to the national guidelines changed, the rate for comparators remained stable. For patients with HL diagnosed in 2004-2009, childbirth rates were comparable to those of the comparators (69.7% vs 70.7%).
The researchers found that, regardless of stage and primary treatment, relapse-free female survivors of HL had birth rates similar to the general population from 3 years after diagnosis. Patients with high-risk disease who received the most gonadtoxic chemotherapy treatment had reduced childbirth rates for the first 3 years, but even their birth rates were similar to comparators after 3 years.

The study only included women who had not relapsed because the treatment after relapse is associated with a high infertility risk.

“In contrast, none of the women who experienced relapse had a childbirth after relapse, underlining the importance of curative first-line treatment also from a fertility perspective,” the authors noted.

Reference

Weibull CE, Johansson ALV, Eloranta S, et al. Contemporarily treated patients with Hodgkin lymphoma have childbearing potential in line with matched comparators [published online July 25, 2018]. J Clin Oncol. doi: 10.1200/JCO.2018.78.3514.

Related Articles

Chemotherapy's Lasting Impact on Male Fertility in Childhood Cancer Survivors
Healthy, but Still Hurting: Challenges of Cancer Survivorship
A Reproductive Endocrinologist Discusses Need to Cover Fertility Intervention in Cancer Care
2018 ASCO Guideline Update: Fertility Preservation in Patients With Cancer
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up